<DOC>
	<DOCNO>NCT00002901</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness docetaxel treat patient advance solid tumor respond standard therapy effective therapy .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Solid Tumors Abnormal Liver Function</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose docetaxel patient advance solid tumor vary degree liver dysfunction . II . Determine effect liver dysfunction patient plasma pharmacokinetics pharmacodynamics therapy . III . Determine utility indocyanine green clearance lidocaine metabolism indicator hepatic elimination docetaxel patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord liver function ( normal v mild v moderate v severe ) . Patients receive docetaxel IV 1 hour . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) receive 2 additional course past CR . Within abnormal liver function stratum , cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Within abnormal liver function stratum , 6 patient treated MTD , possible . Patients normal liver function stratum include control patient follow toxicity , undergo dose escalation . Patients follow survival . PROJECTED ACCRUAL : A maximum 45 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor refractory standard therapy standard therapy exist Eligible tumor , include , limited , follow : Breast Ovarian Head neck Nonsmall cell lung cancer Abnormal liver function Control patient normal liver function enrol Brain metastasis allow control radiotherapy surgery neurologic status currently stable Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 50100 % Life expectancy : At least 1 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL OR Hematocrit least 35 % Hepatic : See Disease Characteristics No active acute hepatitis Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No concurrent cardiovascular disease poorly control currently available treatment severity preclude study Pulmonary : No concurrent pulmonary disease poorly control currently available treatment severity preclude study Other : No concurrent illness ( e.g. , CNS disease ) poorly control currently available treatment severity preclude study No severe infection require treatment Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior radiotherapy 25 % bone marrow Surgery : See Disease Characteristics Recovered major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
</DOC>